Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9377809 | 0.91 | HTR1A (0.39) | HTR2ADRD2HTR1A | |
| SCHEMBL373467 | 0.81 | BCHE (0.44) | HTR2AHTR2CDRD2HTR1A | |
| SCHEMBL12026856 | 0.81 | HIF1A (0.49) | HTR2ADRD2HTR1AGRM4 | |
| SCHEMBL5905924 | 0.81 | CDC7 (0.46) | HTR2AHTR2CDRD2GRM4 | |
| Hydrochloric Acid SCHEMBL1545403 | 0.80 | BCHE (0.43) | HTR2AHTR2CDRD2HTR1A | |
| SCHEMBL5995383 | 0.80 | BCHE (0.43) | HTR2ADRD2HTR1A | |
| SCHEMBL23175425 | 0.79 | DRD2 (0.46) | HTR2ADRD2HTR1A | |
| Hydrochloric Acid SCHEMBL7256201 | 0.75 | DRD2 (0.47) | HTR2AKCNH2DRD2HTR1A | |
| SCHEMBL9274343 | 0.75 | SSTR4 (0.36) | HTR2ADRD2HTR1A | |
| Hydrochloric Acid SCHEMBL7256202 | 0.74 | DRD2 (0.43) | HTR2AKCNH2DRD2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0730594-B1 | 9-HYDROXY-PYRIDO [1,2-a]PYRIMIDIN-4-ONE ETHER DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 1999-09-08 | — | — | EP | claimed |
| EP-0730594-A1 | NOVEL 9-HYDROXY-PYRIDO [1,2-a]PYRIMIDIN-4-ONE ETHER DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-09-11 | — | — | EP | claimed |
| WO-1995014691-A1 | NOVEL 9-HYDROXY-PYRIDO[1,2-a]PYRIMIDIN-4-ONE ETHER DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1995-06-01 | — | — | WO | claimed |
| EP-0368388-B1 | 3-Piperidinyl-1,2-benzisoxazoles | JANSSEN PHARMACEUTICA NV (BE) | 1995-05-10 | — | — | EP | claimed |
| EP-0368388-A2 | 3-Piperidinyl-1,2-benzisoxazoles | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-05-16 | — | — | EP | claimed |
| JP-2191276-A | — | — | None | — | — | JP | disclosed |
| US-11040041-B2 | Method of treating pulmonary arterial hypertension | Cipla (UK) Limited (GB) | 2021-06-22 | — | — | US | disclosed |
| US-20200155557-A1 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION | Cipla (UK) Limited (IN) | 2020-05-21 | — | — | US | disclosed |
| US-10576083-B2 | Method of treating pulmonary arterial hypertension | Cipla (UK) Limited (IN) | 2020-03-03 | — | — | US | disclosed |
| US-20170035765-A1 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION | Cipla (UK) Limited (IN) | 2017-02-09 | — | — | US | disclosed |
| WO-2016199170-A2 | PALIPERIDONE PALMITATE PARTICLES AND COMPOSITIONS THEREOF | CIPLA LIMITED (IN) | 2016-12-15 | — | — | WO | disclosed |
| EP-2235009-B1 | SYNTHESIS OF PALIPERIDONE | SYNTHON BV (NL) | 2013-10-30 | — | — | EP | disclosed |
| EP-0368388-A2 | 3-Piperidinyl-1,2-benzisoxazoles | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-05-16 | — | — | EP | disclosed |
| EP-0368388-A2 | 3-Piperidinyl-1,2-benzisoxazoles | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-05-16 | — | — | EP | disclosed |
| EP-0357134-A1 | Antihypertensive 3-piperidinyl-indazole derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-03-07 | — | — | EP | disclosed |
| EP-0353821-A2 | Antipsychotic 3-piperazinyl-benzazole derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-02-07 | — | — | EP | disclosed |
| US-4804663-A | PSYCHOLOGICAL DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-02-14 | — | — | US | disclosed |
| US-4804663-A | PSYCHOLOGICAL DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-02-14 | — | — | US | disclosed |
| EP-0196132-A2 | 1,2-Benzisoxazol-3-yl and 1,2-benzisothiazol-3-yl derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1986-10-01 | — | — | EP | disclosed |
| EP-0196132-A2 | 1,2-Benzisoxazol-3-yl and 1,2-benzisothiazol-3-yl derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1986-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10576083-B2 | Method of treating pulmonary arterial hypertension | PAH, PDE3B, NPPA | HTR2A 553/4885HTR2C 975/4885KCNH2 148/4885 |
| US-20200155557-A1 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION | PAH, PDE3B, NPPA | HTR2A 553/4885HTR2C 975/4885KCNH2 148/4885 |
| US-20170035765-A1 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION | PAH, PDE3B, NPPA | HTR2A 553/4885HTR2C 975/4885KCNH2 148/4885 |
| US-11040041-B2 | Method of treating pulmonary arterial hypertension | PAH, PDE3B, NPPA | HTR2A 553/4885HTR2C 975/4885KCNH2 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.